Biotech and Life Sciences IPOs

• SOPHiA GENETICS, GH Research, Cyteir Therapeutics, Molecular Partners, Akoya Biosciences, LAVA Therapeutics, Prometheus Biosciences, Inventiva, Generation Bio, ADC Therapeutics, Ayala Pharmaceuticals, Beam Therapeutics, Progyny, Innate Pharma S.A., BioNTech SE, Stoke Therapeutics, Orchard Therapeutics plc, Aptinyx Inc., Magenta Therapeutics, Inc., Solid Biosciences Inc., InflaRx N.V., Kala Pharmaceuticals, Inc., Dova Pharmaceuticals, Inc., Jounce Therapeutics, Inc., Patheon N.V., Cynapsus Therapeutics Inc. and Oxford Immunotec.

Consumer Retail Work

• IPOs for companies including ON Running and Krispy Kreme. Advice to VF on its spinoff of Kontoor Brands. Multiple types of stock and bond offerings for companies including Kontoor Brands, VF and Shake Shack.

SPAC IPOs

• Decarbonization Plus Acquisition Corp. II and III, Disruptive Acquisition Corporation I, Virgin Group Acquisition Corp. II, Kadem Sustainable Impact Corp., Silver Spike Acquisition Corp. II, Frontier Acquisition Corp., PWP Forward Acquisition Corp. I, Aurora Acquisition Corp., Anzu Special Acquisition Corp. I, Freedom Acquisition I Corp., Austerlitz Acquisition Corporation I and II, Soaring Eagle Acquisition Corp., Figure Acquisition Corp. I, Tuatara Capital Acquisition Corporation, Priveterra Acquisition Corp., Thimble Point Acquisition Corp., CC Neuberger Principal Holdings III, Climate Real Impact Solutions II, Science Strategic Acquisition Corp. and Primavera Capital Acquisition Corp. among many more.

Other Work

• She has also participated in securities offerings by Fortune 500 companies such as Abbott, DXC, Hess and Lockheed Martin.
• Deanna has also represented virtually all the major investment banks, including JPMorgan Chase, Citi, Goldman Sachs and Morgan Stanley as underwriters’ counsel in equity and debt offerings and regularly advises investment banking clients on securities law-related matters.